CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Eliquent›
Library
Eliquent

Eliquent

Eliquent Life Sciences guides drug, biotech, and device makers through global regulatory approval.

Operating headquarters
Washington, DC, US🇺🇸
Founded
2004
Loading
Overview
Compare
Employees
News
Library

Eliquent - Library

eliquent.com·Crawled Oct 10, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. Cell & Gene Therapy Consulting and ATMP Solutions/cgt-atmp-solutions

    End-to-end CGT & ATMP consulting—from regulatory strategy to implementation and lifecycle support.

  2. ELIQUENT Beyond The Model/eliquent-beyond-the-model

    The FDA now reads your submissions with AI. Your competitors run the same AI models you do. And when an output is wrong, the liability is still yours.

  3. INFO SHEET: QMSR Solutions/info-sheet-qmsr-solutions

    DOWNLOAD: QMSR Info Sheet SOLUTION: Quality & Compliance Capabilities SOLUTION: QMSR Capabilities…

  4. INFO SHEET: Regulatory Writing Solutions/info-sheet-regulatory-writing-solutions

    DOWNLOAD: Regulatory Writing Info Sheet SOLUTION: Regulatory Affairs Capabilities SOLUTION: Regulatory Writing Capabilities…

Blog

6 pages
  1. ENGAGE with ELIQUENT: Regulatory Roadmap Podcast/engage-with-eliquent-regulatory-roadmap-podcast

    Listen as former FDA senior officials share valuable perspectives and behind-the-scenes insights on the FDA’s transition to a new presidential administration.

  2. LDT Resources/ldt-resources

    LDT Resources Stay ahead of the evolving LDT landscape with ELIQUENT’s LDT Resource Hub. You’ll find expert-driven content, insights…

  3. QMSR Resources/safety-communications-enabling-clarity-in-pharmacovigilance

    As regulatory scrutiny intensifies and safety data grows increasingly complex, biopharmaceutical organizations must move beyond fragmented…

  4. Regulatory Resources/regulatory-resources

    ELIQUENT’s regulatory resources feature a curated library of ELIQUENT materials designed to help you learn more about our expertise, services, and approach.

Press

6 pages
  1. Dr. Celia Witten Joins Eliquent from FDA Center/resource/dr-celia-witten-former-deputy-director-of-fdas-center-for-biologics-joins-eliquent

    ELIQUENT Life Sciences today announced that Celia Witten, M.D., Ph.D., former Deputy Director of the U.S. Food and Drug Administration’s (FDA) Center for…

  2. ELIQUENT Acquires Azzur Consulting/resource/eliquent-acquires-azzur-consulting

    Strategic Acquisition Strengthens Full-Service Quality & Compliance Capabilities ELIQUEN­­T Life Sciences today announced the acquisition of Azzur Consulting…

  3. Otsuka Holdings Autoimmune Disease Strategy 2024/resource/otsuka-holdings-accelerates-mid-to-long-term-strategy-in-autoimmune-diseases-with-8-development-programs

    Introduction to Strategic Focus on Autoimmune Diseases According to a news article (大塚HD・井上社長兼CEO　自己免疫領域に８つの開発品　「中長期的視点に基づく戦略的投資」と位置付け | ニュース | ミクスOnline)…

  4. Radiopharmaceutical EOP2 Meeting FDA Success Case/resource/eliquent-outcomes-fda-end-of-phase-2-eop2-meeting-success-for-a-radiopharmaceutical-company

    Download Case Study PDF Learn More about ELIQUENT’s Radiopharmaceutical Solutions…

Careers & Hiring

1 page
  1. Join our Team/careers

    Work with ELIQUENT: Advance your career in life-sciences consulting and make a difference in global health.

Team

6 pages
  1. ELIQUENT Experts Council/eliquent-experts-council

    The ELIQUENT Experts Council is a select, senior advisory ecosystem of former regulators and industry leaders, designed to pressure-test strategy, mitigate risk…

  2. Jeff Boyd/team/jeff-boyd

    Jeff Boyd leads ELIQUENT’s global CDMO business, bringing together the firm’s Regulatory, Quality & Compliance, and GxP Engineering capabilities to help…

  3. Lynne Ensor/team/lynne-ensor

    As a Partner at ELIQUENT Life Sciences, Dr. Lynne Ensor provides strategic regulatory and compliance consulting to the pharmaceutical and biotechnology sectors.

  4. Marissa Brykman/team/marissa-brykman

    Marissa is a Senior Vice President in the Quality and Compliance Practice, where she provides strategic guidance to life science companies on a broad range of…

About

2 pages
  1. About/about

    Introducing ELIQUENT Life Sciences ELIQUENT Life Sciences is a leading global consulting group delivering regulatory affairs, pharmacovigilance, quality…

  2. ESG & Sustainability/esg-sustainability

    Learn how Eliquent integrates Environmental, Social, and Governance principles into operations.

Homepage

1 page
  1. Homepage/

    ELIQUENT Life Sciences delivers the answers and solutions global life sciences companies need to gain and maintain market authorization for their products.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Updated: October 2025 ELIQUENT Life Sciences, Inc. and its subsidiaries (“Eliquent”/ “we”/ “us”/ “our”) respects an individual’s right to privacy.

Coverage

6 items
  1. Wendy Sanhai Joins ELIQUENT Life Sciences Boardmpo-mag.com/breaking-news/wendy-sanhai-joins-eliquent-life-sciences-board/

    ELIQUENT Life Sciences adds Dr. Wendy Sanhai to its board. Sanhai was a senior director at GlaxoSmithKline.

    Feb 2025 · Medical Product OutsourcingNews article

  2. ELIQUENT Life Sciences Announces: Rob Wojciechowski Named Chief Operations Officerfinancialpost.com/pmn/business-wire-news-releases-pmn/eliquent-life-sciences-announces-rob-wojciechowski-named-chief-operations-officer

    ELIQUENT Life Sciences names Rob Wojciechowski chief operations officer. The company describes itself as a global regulatory, quality, and safety consulting firm.

    Feb 2025 · financialpostNews article

  3. Rob Wojciechowski Joins ELIQUENT Life Sciencesmpo-mag.com/breaking-news/rob-wojciechowski-joins-eliquent-life-sciences/

    Rob Wojciechowski joins ELIQUENT Life Sciences to lead the company’s consulting practice in Europe and Asia.

    Dec 2024 · Medical Product OutsourcingNews article

  4. ELIQUENT Life Sciences Recruits Former FDA Senior Executives to its C-Suitempo-mag.com/breaking-news/eliquent-life-sciences-recruits-former-fda-senior-executives-to-its-c-suite/

    ELIQUENT Life Sciences has recruited former FDA senior executives John Taylor and Michele Dougherty to its C-suite. The two executives now lead ELIQUENT’s Quality and Regulatory practice areas.

    May 2024 · Medical Product OutsourcingNews article